![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
SURVEYOR-I: 100% SVR12 AND FAVORABLE SAFETY OF ABT-493 + ABT-530 ADMINISTERED FOR 12 WEEKS IN NON-CIRRHOTIC PATIENTS WITH GENOTYPES 4, 5, OR 6 INFECTION
|
|
|
Reported by Jules Levin
Digestive Disease Week
San Diego, California
23 May 2016
Edward Gane1, Jacob Lalezari2, Armen Asatryan3, Susan Greenbloom4, Tarek Hassanein5, Teresa I Ng3, Ran Liu3, Chih-Wei Lin3, Jens Kort3, Federico J Mensa3
1Liver Unit, Auckland City Hospital, Auckland, New Zealand; 2eStudySite, San Diego, California, United States;
3AbbVie Inc., North Chicago, Illinois, United States; 4Toronto Digestive Disease Associates, Toronto, Ontario, Canada; 5Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States
![DDW1](../images/052616/052616-6/DDW1.gif)
![DDW2](../images/052616/052616-6/DDW2.gif)
![DDW3](../images/052616/052616-6/DDW3.gif)
![DDW4](../images/052616/052616-6/DDW4.gif)
![DDW5](../images/052616/052616-6/DDW5.gif)
![DDW6](../images/052616/052616-6/DDW6.gif)
![DDW7](../images/052616/052616-6/DDW7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|